Laval, Québec-based Altasciences Group, which through a group of companies, including Algorithme Pharma Inc., provides early-stage clinical drug development services in Phase I and Phase II testing, has bought Vince and Associates Clinical Research of Overland Park, Kan., which operates in the same sector. The acquisition price was not disclosed. Altasciences-Algorithme is a portfolio investment of Canadian mid-market buyout firm Kilmer Capital Partners. Kilmer has invested in the holding company’s assets since 2007.
Vince and Associates Clinical Research Joins the Altasciences Group
LAVAL, Québec–(BUSINESS WIRE)–The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
“We continue to benefit from the industry shift towards these types of complex studies and joining the Altasciences team will significantly enhance our capabilities while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients.”
Based in Overland Park, Kansas since 2001, Vince and Associates has become an established industry leader in the successful recruitment and retention of special populations in complex early development clinical trials. The Vince and Associates approach, where study teams are led by highly experienced Principal Investigators intricately involved in all aspects of the clinical trial process, has generated significant industry demand for their services from both large pharmaceutical and biotechnology clients.
“We continue to benefit from the industry shift towards these types of complex studies and joining the Altasciences team will significantly enhance our capabilities while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients,” said Dr. Brad Vince, Founder, President and Medical Director of Vince and Associates. Dr. Vince will continue to act as the CEO and Medical Director.
Altasciences, owned by Kilmer Capital Partners, also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
Altasciences, through its group of companies, provides comprehensive early stage clinical drug development services in Phase I/ IIa, including the necessary support services in this critical stage of drug development.
Leveraging the extensive expertise and capabilities available, the strategy is to maintain the core competencies and identity of each company and ensure that they benefit from the value of being part of a common larger organization focused on excellence in customer service, operating under the ALTASCIENCES umbrella name.
About Vince & Associates Clinical Research
Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a “Center of Research Excellence”, Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model® of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.
Vince & Associates recently opened a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This new unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.
Edgemont Capital Partners, a leading healthcare investment banking firm, acted as exclusive financial advisor to Vince and Associates Clinical Research.
About Kilmer Capital Partners
Kilmer Capital Partners is a leader in making private equity investments in mid-sized businesses undergoing periods of rapid growth, significant change or ownership transition. The Principals of Kilmer Capital have the strategic, operational, acquisition and financial expertise and experience to assist management teams in achieving their strategic visions.
Catherine Konidas, 450-973-6077
Photo courtesy of Shutterstock.